The phylogenetic proximity between non-human primate species and humans is reflected by a high degree of immunological similarity. Non-human primates therefore provide important experimental models for disorders in the human population that are caused by the immune system, such as autoimmune diseases. In this paper we describe non-human primate models of multiple sclerosis, a chronic inflammatory and demyelinating disease of the human central nervous system. While reviewing data from the literature and our own research we will discuss the unique role of such models in the research of basic disease mechanisms and the development of new therapies
The attrition rate of new drugs for central nervous system diseases including multiple sclerosis (MS...
The increasing prevalence of chronic autoimmune-mediated inflammatory disorders (AIMIDs) in aging hu...
New drugs often fail in the translation from the rodent experimental autoimmune encephalomyelitis (E...
Despite years of intensive research into multiple sclerosis (MS) scientists have not yet succeeded i...
The many, highly specific, biological therapies for immune-based diseases create a need for valid pr...
Ageing Western societies are facing an increasing prevalence of chronic inflammatory and degenerativ...
Multiple sclerosis (MS) is one of the most intensively studied immune-based inflammatory diseases (I...
Introduction: The translation of scientific discoveries made in animal models into effective treatme...
The efficacy of many new immunomodulatory therapies for multiple sclerosis (MS) patients has often b...
textabstractMultiple sclerosis (MS) is a major cause of disability in young adults affecting approxi...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Due to their genetic and immunological proximity to humans, the common marmoset, Callithrix jacchus,...
Multiple sclerosis is a serious neurological disease that affects 1 in 1000 young adults in Europe a...
The work published in this issue by Claude Genain and col-leagues (1) has important implications for...
Background: Multiple sclerosis (MS) develops exclusively in humans. Non-human primates are resistant...
The attrition rate of new drugs for central nervous system diseases including multiple sclerosis (MS...
The increasing prevalence of chronic autoimmune-mediated inflammatory disorders (AIMIDs) in aging hu...
New drugs often fail in the translation from the rodent experimental autoimmune encephalomyelitis (E...
Despite years of intensive research into multiple sclerosis (MS) scientists have not yet succeeded i...
The many, highly specific, biological therapies for immune-based diseases create a need for valid pr...
Ageing Western societies are facing an increasing prevalence of chronic inflammatory and degenerativ...
Multiple sclerosis (MS) is one of the most intensively studied immune-based inflammatory diseases (I...
Introduction: The translation of scientific discoveries made in animal models into effective treatme...
The efficacy of many new immunomodulatory therapies for multiple sclerosis (MS) patients has often b...
textabstractMultiple sclerosis (MS) is a major cause of disability in young adults affecting approxi...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
Due to their genetic and immunological proximity to humans, the common marmoset, Callithrix jacchus,...
Multiple sclerosis is a serious neurological disease that affects 1 in 1000 young adults in Europe a...
The work published in this issue by Claude Genain and col-leagues (1) has important implications for...
Background: Multiple sclerosis (MS) develops exclusively in humans. Non-human primates are resistant...
The attrition rate of new drugs for central nervous system diseases including multiple sclerosis (MS...
The increasing prevalence of chronic autoimmune-mediated inflammatory disorders (AIMIDs) in aging hu...
New drugs often fail in the translation from the rodent experimental autoimmune encephalomyelitis (E...